派格生物医药-B今日盘中大涨6.86%，引起了市场的广泛关注。
消息面上，此次股价上涨主要得益于公司核心产品派达康（维培那肽注射液）的商业化进程显著加速。公司此前与腾瑞制药就派达康在中国大陆的独家商业化签署了战略合作协议，腾瑞制药将支付合计约1.4亿港币的权益金，双方确立了累计销售额超过100亿元人民币的核心目标。此外，方舟健客近期与腾瑞制药达成战略合作，派达康将于近期在其互联网医院平台全网首发，标志着这款GLP-1创新药正式进入商业化放量阶段。
派格生物医药是一家专注于慢性病创新疗法研发的公司，其核心产品PB-119（即派达康）为自主开发的长效GLP-1受体激动剂，主要用于治疗2型糖尿病及肥胖症等代谢疾病。受上述系列商业化利好消息驱动，市场对公司未来增长前景的信心得到增强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.